Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation

Immunotherapy

Volumn 1, Issue 4, 2009, Pages 599-621

  Li, Jian Ming ^a   Giver, Cynthia R ^a   Lu, Ying ^a   Hossain, Mohammad S ^a   Akhtari, Mojtaba ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Cytokine; Dendritic cell; Donor lymphocyte infusion; Graft versus host disease; Graft versus leukemia; Immunosuppressant; Natural killer cell

Indexed keywords

ANTIMETABOLITE; BCR ABL PROTEIN; BUSULFAN; CALCINEURIN INHIBITOR; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; CYTOKINE; ETANERCEPT; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HY ANTIGEN; INFLIXIMAB; INTERLEUKIN 11; KERATINOCYTE GROWTH FACTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHOXSALEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOBLASTIN; PREDNISOLONE; PROTEIN WILM TUMOR 1; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG; VORINOSTAT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY SPECIFICITY; ANTINEOPLASTIC ACTIVITY; CELL FUNCTION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; DNA POLYMORPHISM; DONOR LYMPHOCYTE INFUSION; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; LYMPHOMA; MEMORY T LYMPHOCYTE; MESENCHYMAL STEM CELL; METASTASIS; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PUVA; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TUMOR;

ANIMALS; CELL COMMUNICATION; DENDRITIC CELLS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES, REGULATORY; TH1-TH2 BALANCE; VACCINATION;

EID: 77953373822     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/IMT.09.32     Document Type: Review

References (286)

1. Billingham RE, Silvers WK: Quantitative studies on the ability of cells of different origins to induce tolerance of skin homografts and cause runt disease in neonatal mice. J. Exp. Zool. 146, 113-129 (1961).
2. Billingham RE: The biology of graft-versus-host reactions. Harvey Lect. 62, 21-78 (1966). • Addressed three conditions required for the development of graft-versus-host disease (GvHD): donor-derived immunologically competent cells, alloantigen mismatch between donor and host, and host immunocompromised status.
3. Mathe G, Amiel JL, Schwarzenberg L, Cattan A, Schneider M: Haematopoietic chimera in man after allogenic (homologous) bone-marrow transplantation. (Control of the secondary syndrome. Specific tolerance due to the chimerism). Br. Med. J. 2, 1633-1635 (1963).
4. Ferrara JL, Reddy P: Pathophysiology of graft-versus-host disease. Semin. Hematol. 43, 3-10 (2006). • Addressed three steps in the pathophysiology of GvHD: conditioning-induced damage in tissues and proinflammatoy cytokine production, activation of immune cells, and amplification of proinflammtory cytokine production and damage to target tissues and organs.
5. Levine JE, Blazar BR, DeFor T, Ferrara JL, Weisdorf DJ: Long-term follow-up of a Phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT). Biol. Blood Marrow Transplant. 14, 1017-1021 (2008).
6. Del Giudice I, Foa R: New therapies in onco-hematology and new infectious risk factors. Rev. Clin. Exp. Hematol. 9, E1 (2005).
7. Uberti JP, Ayash L, Ratanatharathorn V et al.: Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol. Blood Marrow Transplant. 11, 680-687 (2005).
8. + graft-versus-host-reactive effector cells. J. Immunol. 181, 6820-6828 (2008).
9. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R, Drobyski WR: NF-κB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145. Blood 107, 827-834 (2006). (Pubitemid 43076412)
10. Chakraverty R, Cote D, Buchli J et al.: An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral tissues. J. Exp. Med. 203, 2021-2031 (2006).
11. Ruggeri L, Mancusi A, Burchielli E et al.: Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy 8, 554-558 (2006). •• Described mechanisms by which natural killer (NK) cells separate GvHD from graft-versus-leukemia (GvL) activity through removal of: leukemic cells, recipient T cells that reject the graft, and recipient dendritic cells (DCs) that trigger GvHD. (Pubitemid 44869855)
12. Ferrara JL: Advances in the clinical management of GVHD. Best Pract. Res. Clin. Haematol. 21, 677-682 (2008).
13. Savage P, Gao L, Vento K et al.: Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 103, 4613-4615 (2004). (Pubitemid 38745991)
14. Marijt WA, Heemskerk MH, Kloosterboer FM et al.: Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA 100, 2742-2747 (2003).
15. + antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 108, 2106-2113 (2006). (Pubitemid 44395027)
16. Kebriaei P, Detry MA, Giralt S et al.: Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 110, 3456-3462 (2007). (Pubitemid 350106342)
17. Childs R, Chernoff A, Contentin N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N. Engl. J. Med. 343, 750-758 (2000).
18. Ueno NT, Rizzo JD, Demirer T et al.: Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 41, 537-545 (2008).
19. Horowitz MM, Gale RP, Sondel PM et al.: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555-562 (1990).
20. Butturini A, Gale RP: T cell depletion in bone marrow transplantation for leukemia: current results and future directions. Bone Marrow Transplant. 3, 185-192 (1988). (Pubitemid 18136411)
21. Butturini A, Gale RP: Graft versus leukemia. Immunol. Res. 11, 24-33 (1992).
22. Barrett AJ, van Rhee F: Graft-versus-leukaemia. Baillieres Clin. Haematol. 10, 337-355 (1997).
23. Bacigalupo A, Lamparelli T, Bruzzi P et al.: Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98, 2942-2947 (2001).
24. Wagner JE, Thompson JS, Carter SL, Kernan NA: Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multicentre, randomised Phase II-III trial. Lancet 366, 733-741 (2005).
25. Pavletic SZ, Carter SL, Kernan NA et al.: Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 106, 3308-3313 (2005).
26. Waller EK, Langston AA, Lonial S et al.: Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol. Blood Marrow Transplant. 9, 460-471 (2003).
27. Dao MA, Nolta JA: CD34: to select or not to select? That is the question. Leukemia 14, 773-776 (2000).
28. Champlin RE, Passweg JR, Zhang MJ et al.: T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95, 3996-4003 (2000).
29. Li JM, Giver CR, Waller EK: Graft engineering using ex vivo methods to limit GVHD: fludarabine treatment generates superior GVL effects in allogeneic BMT. Exp. Hematol. 34, 895-904 (2006).
30. Xia G, Truitt RL, Johnson BD: Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol. Blood Marrow Transplant. 12, 397-407 (2006).
31. Klingebiel T, Bader P: Delayed lymphocyte infusion in children given SCT. Bone Marrow Transplant. 41 (Suppl. 2), S23-S26 (2008). • Demonstrated that GvHD was reduced in pediatric patients by delayed donor lymphocyte infusion (DLI) with a narrow (weekly) time schedule, using low initial doses followed by escalating doses of DLI. (Pubitemid 351864702)
32. Johnson BD, Becker EE, Truitt RL: Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol. Blood Marrow Transplant. 5, 123-132 (1999).
33. Mapara MY, Kim YM, Marx J, Sykes M: Donor lymphocyte infusion-mediated graft-versus-leukemia effects in mixed chimeras established with a nonmyeloablative conditioning regimen: extinction of graft-versus-leukemia effects after conversion to full donor chimerism. Transplantation 76, 297-305 (2003). (Pubitemid 36927988)
34. Drobyski WR, Hessner MJ, Klein JP et al.: T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 94, 434-441 (1999).
35. Billiau AD, Fevery S, Rutgeerts O, Landuyt W, Waer M: Crucial role of timing of donor lymphocyte infusion in generating dissociated graft-versus-host and graft-versus-leukemia responses in mice receiving allogeneic bone marrow transplants. Blood 100, 1894-1902 (2002).
36. Miller JS, Weisdorf DJ, Burns LJ et al.: Lymphodepletion followed by donor lymphocyte infusion (DLI) causes significantly more acute graft-versus-host disease than DLI alone. Blood 110, 2761-2763 (2007).
37. Kolb HJ, Schmid C, Chen X et al.: Adoptive immunotherapy in chimeras with donor lymphocytes. Acta Haematol. 110, 110-120 (2003). (Pubitemid 37340190)
38. Dazzi F, Szydlo RM, Cross NC et al.: Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 96, 2712-2716 (2000). (Pubitemid 30770364)
39. Bloor, AJC, Thomson K, Cooper N, Peggs KS, Mackinnon S: Dose-escalated donor lymphocyte infusions post allogeneic transplantation in non-Hodgkin's lymphoma. Blood 106, 2013 (2005).
40. Dazzi F, Szydlo RM, Craddock C et al.: Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 95, 67-71 (2000). (Pubitemid 30017226)
41. + T-cell-depleted graft. Bone Marrow Transplant 31, 121-128 (2003).
42. Mackinnon S, Papadopoulos EB, Carabasi MH et al.: Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 86, 1261-1268 (1995).
43. Bacigalupo A, Soracco M, Vassallo F et al.: Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 19, 927-932 (1997). (Pubitemid 27217661)
44. van Rhee F, Savage D, Blackwell J et al.: Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant 21, 1055-1061 (1998). (Pubitemid 28230672)
45. Edinger M, Powrie F, Chakraverty R: Regulatory mechanisms in graft-versus-host responses. Biol. Blood Marrow Transplant 15, 2-6 (2008).
46. Kolb HJ: Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 112, 4371-4383 (2008).
47. Passweg JR, Tichelli A, Meyer-Monard S et al.: Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 18, 1835-1838 (2004).
48. Schmid C, Labopin M, Nagler A et al.: Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J. Clin. Oncol. 25, 4938-4945 (2007).
49. Rizzieri DA, Koh LP, Long GD et al.: Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J. Clin. Oncol. 25, 690-697 (2007).
50. Huang XJ, Liu DH, Liu KY et al.: Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol. Blood Marrow Transplant 15, 257-265 (2009).
51. Saito TI, Rubio MT, Sykes M: Clinical relevance of recipient leukocyte infusion as antitumor therapy following nonmyeloablative allogeneic hematopoietic cell transplantation. Exp. Hematol. 34, 1271-1277 (2006).
52. Matejkova E, Ocadlikova D, Smejkalova J et al.: Selective depletion of alloreactive T cells and study of anti-tumor activity of specific T cell clones in patients with leukemia. Klin. Onkol. 21, 104-109 (2008).
53. Hartwig UF, Nonn M, Khan S et al.: Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity. Biol. Blood Marrow Transplant 14, 99-109 (2008). (Pubitemid 350286744)
54. Sathe A, Ortega SB, Mundy DI, Collins RH, Karandikar NJ: In vitro methotrexate as a practical approach to selective allodepletion. Biol. Blood Marrow Transplant 13, 644-654 (2007).
55. Boumedine RS, Roy DC: Elimination of alloreactive T cells using photodynamic therapy. Cytotherapy 7, 134-143 (2005).
56. Blazar BR, Lees CJ, Martin PJ et al.: Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions. J. Immunol. 165, 4901-4909 (2000).
57. + CTLs as potent veto cells: coexpression of CD8 and FasL is a prerequisite. Immunity 13, 507-515 (2000).
58. Drobyski WR, Majewski D, Ozker K, Hanson G: Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment./ Immunol. 161, 2610-2619 (1998).
59. Amrolia PJ, Muccioli-Casadei G, Huls H et al.: Adoptive immunotherapy with allodepleted donor T cells improves immune reconstitution after haploidentical stem cell transplantation. Blood 108, 1797-1808 (2006).
60. Mielke S, Nunes R, Rezvani K et al.: A. clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood 111, 4392-4402 (2008).
61. Bonini C, Bordignon C: Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol. Cell Ther. 39, 273-274 (1997).
62. Bonini C, Ferrari G, Verzeletti S et al.: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia (see comments). Science 276, 1719-1724 (1997). (Pubitemid 27421983)
63. Bordignon C, Bonini C, Verzeletti S et al.: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. Hum. Gene Ther. 6, 813-819 (1995).
64. Bonini C, Bondanza A, Perna SK et al.: The suicide gene therapy challenge: how to improve a successful gene therapy approach. Mol. Ther. 15, 1248-1252 (2007).
65. Traversari C, Marktel S, Magnani Z et al.: The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood 109, 4708-4715 (2007). (Pubitemid 46827762)
66. + T cells do not induce graft-versus-host disease. J. Clin. Invest. 112, 101-108 (2003).
67. + T cells mediate graft-versus-leukemia without inducing graft-versus-host disease. Blood 111, 2476-2484 (2008).
68. Chen BJ, Cui X, Sempowski GD, Liu C, Chao NJ: Transfer of allogeneic CD62L-memory T cells without graft-versus-host disease. Blood 103, 1534-1541 (2004). (Pubitemid 38168675)
69. Giver CR, Montes RO, Mittelstaedt S et al.: Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects. Biol. Blood Marrow Transplant. 9, 616-632 (2003).
70. Giver CR, Li JM, Hossain MS, Lonial S, Waller EK: Reconstructing immunity after allogeneic transplantation. Immunol. Res. 29, 269-282 (2004).
71. Kabelitz D, Glatzel A, Wesch D: Antigen recognition by human γδ T lymphocytes. Int. Arch. Allergy Immunol. 122, 1-7 (2000).
72. Poccia F, Cipriani B, Vendetti S et al.: CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive V γ 9V δ 2 T lymphocytes. J. Immunol. 159, 6009-6017 (1997). (Pubitemid 127471537)
73. Hayday A, Tigelaar R: Immunoregulation in the tissues by γδ T cells. Nat. Rev. Immunol. 3, 233-242 (2003).
74. Tschop J, Martignoni A, Goetzman HS et al.: γδ T cells mitigate the organ injury and mortality of sepsis. J. Leukoc. Biol. 83, 581-588 (2008).
75. Leslie DS, Vincent MS, Spada FM et al.: CD1-mediated γ/δ T cell maturation of dendritic cells. J. Exp. Med. 196, 1575-1584 (2002).
76. Maeda Y, Reddy P, Lowler KP, Liu C, Bishop DK, Ferrara JL: Critical role of host γδ T cells in experimental acute graft-versus-host disease. Blood 106, 749-755 (2005).
77. + predicts the risk of acute graft versus host disease after transplantation of allogeneic peripheral blood stem cells from unrelated donors. Clin. Cancer Res. 13, 2916-2922 (2007).
78. Drobyski WR, Vodanovic-Jankovic S, Klein J: Adoptively transferred γ δ T cells indirectly regulate murine graft-versus-host reactivity following donor leukocyte infusion therapy in mice. J. Immunol. 165, 1634-1640 (2000). (Pubitemid 30604602)
79. Vodanovic-Jankovic S, Drobyski WR: γδT cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection. Biol. Blood Marrow Transplant 12, 1125-1134 (2006). (Pubitemid 44660864)
80. Godder KT, Henslee-Downey PJ, Mehta J et al.: Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant 39, 751-757 (2007).
81. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155, 1151-1164 (1995).
82. Maloy KJ, Powrie F: Regulatory T cells in the control of immune pathology. Nat. Immunol. 2, 816-822 (2001). •• Concise review covering immunobiology of regulatory T cells: generation, phenotypes, subpopulations and functional mechanisms.
83. + T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193, 1285-1294 (2001).
84. + immunoregulatory T cells of donor origin suppress alloreactivity after BMT. Biol. Blood Marrow Transplant 8, 525-535 (2002).
85. + regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Exp. Med. 196, 389-399 (2002).
86. + immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J. Exp. Med. 196, 401-406 (2002).
87. + regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat. Med. 9, 1144-1150 (2003).
88. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
89. + regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood 110, 1689-1697 (2007). (Pubitemid 47443988)
90. Miura Y, Thoburn CJ, Bright EC et al.: Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104, 2187-2193 (2004). (Pubitemid 39297878)
91. + regulatory T cells in patients with chronic graft-versus-host disease. Blood 106, 2903-2911 (2005). (Pubitemid 41510772)
92. high regulatory T cells. Blood 103, 2410-2416 (2004). (Pubitemid 38326268)
93. Janson PC, Winerdal ME, Marits P et al.: FOXP3 promoter demethylation reveals the committed Treg population in humans. PLoS ONE 3, E1612 (2008). (Pubitemid 351850770)
94. + immune regulatory cells inhibits graft-versus-host disease lethality. Blood 99, 3493-3499 (2002).
95. Nguyen VH, Zeiser R, Negrin RS: Role of naturally arising regulatory T cells in hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 12, 995-1009 (2006).
96. + T regulatory cells and promote organ transplant tolerance. J. Immunol. 178, 7018-7031 (2007). (Pubitemid 46847428)
97. Gatza E, Rogers CE, Clouthier SG et al.: Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 112, 1515-1521 (2008).
98. Johnston L: Acute graft-versus-host disease: differing risk with differing graft sources and conditioning intensity. Best Pract. Res. Clin. Haematol. 21, 177-192 (2008).
99. Rocha V, Labopin M, Sanz G et al.: Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N. Engl. J. Med. 351, 2276-2285 (2004).
100. Laughlin MJ, Eapen M, Rubinstein P et al.: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N. Engl. J. Med. 351, 2265-2275 (2004).
101. Weisdorf DJ, Anasetti C, Antin JH et al.: Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation. Blood 99, 1971-1977 (2002).
102. Schmitz N, Eapen M, Horowitz MM et al.: Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 108, 4288-4290 (2006). (Pubitemid 44913306)
103. Eapen M, Logan BR, Confer DL et al.: Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol. Blood Marrow Transplant 13, 1461-1468 (2007). (Pubitemid 350091382)
104. Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC: A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol. Blood Marrow Transplant 13, 444-453 (2007). (Pubitemid 46421885)
105. Ruggeri L, Mancusi A, Capanni M et al.: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 110, 433-440 (2007). (Pubitemid 47026866)
106. Ruggeri L, Capanni M, Urbani E et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002). (Pubitemid 34229476)
107. Savani BN, Rezvani K, Mielke S et al.: Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 107, 1688-1695 (2006). (Pubitemid 43242410)
108. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood 100, 1935-1947 (2002).
109. Zamai L, Ponti C, Mirandola P et al.: NK cells and cancer. J. Immunol. 178, 4011-4016 (2007).
110. Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A: Use of natural killer cells in hematopoetic stem cell transplantation. Bone Marrow Transplant. 35, 637-643 (2005). (Pubitemid 40520947)
111. Vago L, Forno B, Sormani MP et al.: Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 112, 3488-3499 (2008).
112. Shlomchik WD, Couzens MS, Tang CB et al.: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285, 412-415 (1999).
113. Teshima T, Ordemann R, Ready P et al.: Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat. Med. 8, 575-581 (2002).
114. Duffner UA, Maeda Y, Cooke KR et al.: Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J. Immunol. 172, 7393-7398 (2004). (Pubitemid 38747600)
115. Matte CC, Liu J, Cormier J et al.: Donor APCs are required for maximal GVHD but not for GVL. Nat. Med. 10, 987-992 (2004).
116. Li JM, Waller EK: Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Biol. Blood Marrow Transplant. 10, 540-551 (2004).
117. Taylor PA, Ehrhardt MJ, Lees CJ et al.: TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood (2008).
118. Li JM, Gorechlad J, Larsen CP, Waller EK: Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation. Biol. Blood Marrow Transplant 12, 1239-1249 (2006). (Pubitemid 44858269)
119. Welniak LA, Blazar BR, Murphy WJ: Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu. Rev. Immunol. 25, 139-170 (2007). •• Comprehensive review of immunobiology involved in allohematopoietic stem cell transplantation (HSCT) and factors that influence the success of therapy: host-versus-graft reactions, GvHD, graft-versus-tumor (GvT) activity, and transplant-related opportunistic infections. Also summarizes some new strategies to optimize GvT and improve overall immune function while reducing GvHD and graft rejection.
120. Waller EK, Li JM: Donor dendritic cells dance the do-si-do in allogeneic transplantation. Blood 112, 3007-3008 (2008).
121. Smits HH, de Jong EC, Wierenga EA, Kapsenberg ML: Different faces of regulatory DCs in homeostasis and immunity. Trends Immunol. 26, 123-129 (2005).
122. Jiang A, Bloom O, Ono S et al.: Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 27, 610-624 (2007). (Pubitemid 47615505)
123. + T cell tolerance through PD-I and CTLA-4. Nat. Immunol. 6, 280-286 (2005).
124. + regulatory T cells. J. Immunol. 181, 6923-6933 (2008).
125. Ferguson TA, Kazama H: Signals from dying cells: tolerance induction by the dendritic cell. Immunol. Res. 32, 99-108 (2005).
126. + dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum. 54, 887-898 (2006).
127. + dendritic cells play an important role in intravenous tolerance and the suppression of experimental autoimmune encephalomyelitis. J. Immunol. 181, 2483-2493 (2008).
128. Legge KL, Gregg RK, Maldonado-Lopez R et al.: On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J. Exp. Med. 196, 217-227 (2002).
129. Li JM, Southerland LT, Lu Y et al.: Activation, immune polarization, and graft-versus-leukemia activity of donor T cells is regulated by specific subsets of donor bone marrow dendritic cell precursors in allogeneic hematopoietic stem cell transplantation. J. Immunol. (2009) (In Press).
130. Hackstein H, Thomson AW: Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat. Rev. Immunol. 4, 24-34 (2004).
131. Chorny A, Gonzalez-Rey E, Fernandez-Martin A et al.: Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc. Natl Acad. Sci. USA 102, 13562-13567 (2005).
132. Southerland LT, Li JM, Hossain MS et al.: The absence of vasoactive intestinal peptide augments allo-reactivity and the anti-viral response in bone marrow transplantation. Blood 110, 3863(2007).
133. Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL: Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363-1372 (1999).
134. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR: The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J. Immunol. 181, 5396-5404 (2008).
135. Williams CA, Harry RA, McLeod JD: Apoptotic cells induce dendritic cell-mediated suppression via interferon-γ-induced IDO. Immunology 124, 89-101 (2008).
136. Lopez AS, Alegre E, LeMaoult J, Carosella E, Gonzalez A: Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells. Mol. Immunol. 43, 2151-2160 (2006).
137. high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur. J. Immunol. 37, 3054-3062 (2007).
138. + T regulatory cells stimulate IFN-γ-independent CD152-mediated activation of tryptophan catabolism that provides dendritic cells with immune regulatory activity in mice unresponsive to staphylococcal enterotoxin Br. J. Immunol. 179, 910-917 (2007).
139. Munn DH, Sharma MD, Lee JR et al.: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297, 1867-1870 (2002).
140. Munn DH, Sharma MD, Hou D et al.: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114, 280-290 (2004).
141. Orabona C, Puccetti P, Vacca C et al.: Toward the identification of a tolerogenic signature in IDO-competent dendritic cells. Blood 107, 2846-2854 (2006).
142. Terness P, Chuang JJ, Bauer T, Jiga L, Opelz G: Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood 105, 2480-2486 (2005).
143. Braun D, Longman RS, Albert ML: A two-step induction of indoleamine 2,3
144. Tokita D, Mazariegos GV, Zahorchak AF et al.: High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation 85, 369-377 (2008). (Pubitemid 351322760)
145. Schreiner B, Bailey SL, Shin T, Chen L, Miller SD: PD-1 ligands expressed on myeloid-derived APC in the CNS regulate T-cell responses in EAE. Eur. J. Immunol. 38, 2706-2717 (2008).
146. + T cell activation. Eur. J. Immunol. 36, 2472-2482 (2006). (Pubitemid 44420603)
147. Caplan AI: Mesenchymal stem cells. J. Orthop. Res. 9, 641-650 (1991).
148. Barry FP, Murphy JM: Mesenchymal stem cells: clinical applications and biological characterization. Int. J. Biochem. Cell Biol. 36, 568-584 (2004).
149. Bartholomew A, Sturgeon C, Siatskas M et al.: Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30, 42-48 (2002).
150. Aggarwal S, Pittenger MF: Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005).
151. Polchert D, Sobinsky J, Douglas G et al.: IFN-γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease. Eur. J. Immunol. 38, 1745-1755 (2008).
152. Rafei M, Hsieh J, Fortier S et al.: Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112, 4991-4998 (2008).
153. Badillo AT, Peranteau WH, Heaton TE, Quinn C, Flake AW: Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease. Br. J. Haematol. 141, 224-234 (2008).
154. Le Blanc K, Frassoni F, Ball L et al.: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a Phase II study. Lancet 371, 1579-1586 (2008). (Pubitemid 351626841)
155. Ringden O, Uzunel M, Rasmusson I et al.: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81, 1390-1397 (2006). (Pubitemid 43847148)
156. Ning H, Yang F, Jiang M et al.: The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22, 593-599 (2008).
157. Sawada H, Morimoto H, Wake A et al.: Allogeneic peripheral blood stem cell transplantation in 30 patients with hematologic disorders. Rinsho Ketsueki 39, 1085-1091 (1998).
158. Ayuk F, Diyachenko G, Zabelina T et al.: Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp. Hematol. 36, 1047-1054 (2008).
159. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Sehgal S, Vallera DA: In vivo inhibition of cytokine responsiveness and graft-versus-host disease mortality by rapamycin leads to a clinical-pathological syndrome discrete from that observed with cyclosporin A. Blood 87, 4001-4009 (1996).
160. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA: Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia- causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J. Immunol. 160, 5355-5365 (1998). (Pubitemid 28267824)
161. Okamura K, Watanabe T, Onishi T et al.: Successful allogeneic unrelated bone marrow transplantation using reduced-intensity conditioning for the treatment of X-linked adrenoleukodystrophy in a one-yr-old boy. Pediatr. Transplant 13, 130-133 (2009).
162. Hoyt R, Ritchie DS, Roberts AW et al.: Cyclosporin, methotrexate and prednisolone for graft-versus-host disease prophylaxis in allogeneic peripheral blood progenitor cell transplants. Bone Marrow Transplant 41, 651-658 (2008).
163. Cutler C, Kim HT, Hochberg E et al: Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol. Blood Marrow Transplant 10, 328-336 (2004). (Pubitemid 38519571)
164. Chen BJ, Morris RE, Chao NJ: Graft-versus-host disease prevention by rapamycin: cellular mechanisms. Biol. Blood Marrow Transplant 6, 529-536 (2000).
165. Adorini L, Giarratana N, Penna G: Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin. Immunol. 16, 127-134 (2004).
166. Kohno A, Morishita Y, Iida H et al.: Low-dose cyclosporin A with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen-identical siblings: a prospective Phase II study in Japanese patients. Int. J. Hematol. 84, 83-89 (2006).
167. Teachey DT, Sheen C, Hall J et al.: mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood 112, 2020-2023 (2008).
168. Teachey DT, Obzut DA, Cooperman J et al.: The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107, 1149-1155 (2006). (Pubitemid 43156317)
169. Armand P, Gannamaneni S, Kim HT et al.: Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J. Clin. Oncol. 26, 5767-5774 (2008).
170. + T cells. Bone Marrow Transplant 39, 537-545 (2007). (Pubitemid 46629589)
171. Marks PA, Miller T, Richon VM: Histone deacetylases. Curr. Opin. Pharmacol. 3, 344-351 (2003).
172. Leoni F, Zaliani A, Bertolini G et al.: The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl Acad. Sci. USA 99, 2995-3000 (2002).
173. Reddy P, Maeda Y, Hotary K et al.: Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl Acad. Sci. USA 101, 3921-3926 (2004).
174. Leng C, Gries M, Ziegler J et al.: Reduction of graft-versus-host disease by histone deacetylase inhibitor suberonylanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol. 34, 776-787 (2006).
175. Sasakawa Y, Naoe Y, Sogo N et al.: Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem. Pharmacol. 69, 603-616 (2005).
176. Xu WS, Parmigiani RB, Marks PA: Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26, 5541-5552 (2007).
177. Fowler DH, Gress RE: Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma. Leuk. Lymphoma 38, 221-234 (2000).
178. Korn T, Bettelli E, Oukka M, Kuchroo VK: IL-17 and Th17 Cells. Annu. Rev. Immunol. (2009).
179. Antin JH, Weinstein HJ, Guinan EC et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84, 1342-1348 (1994).
180. Antin JH, Weisdorf D, Neuberg D et al.: Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood 100, 3479-3482 (2002). (Pubitemid 35303912)
181. Holler E, Kolb HJ, Hintermeier-Knabe R et al.: Role of tumor necrosis factor α in acute graft-versus-host disease and complications following allogeneic bone marrow transplantation. Transplant Proc. 25, 1234-1236 (1993). (Pubitemid 23078969)
182. Choi SW, Kitko CL, Braun T et al.: Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 112, 1539-1542 (2008).
183. Cooke KR, Hill GR, Gerbitz A et al.: Tumor necrosis factor-α neutralization reduces lung injury after experimental allogeneic bone marrow transplantation. Transplantation 70, 272-279 (2000). (Pubitemid 30602742)
184. Piguet PF, Grau GE, Allet B, Vassalli P: Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J. Exp. Med. 166, 1280-1289 (1987).
185. Borsotti C, Franklin AR, Lu SX et al.: Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood 110, 783-786 (2007).
186. Hamadani M, Hofmeister CC, Jansak B et al.: Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. Biol. Blood Marrow Transplant 14, 783-789 (2008). (Pubitemid 351784372)
187. Kobbe G, Schneider P, Rohr U et al.: Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFα antibody. Bone Marrow Transplant 28, 47-49 (2001). (Pubitemid 32707616)
188. Couriel DR, Hicks K, Giralt S, Champlin RE: Role of tumor necrosis factor-α inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation. Curr. Opin. Oncol. 12, 582-587 (2000).
189. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Downey JP: Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. Transplantation 73, 665-667 (2002). (Pubitemid 34193637)
190. Couriel D, Saliba R, Hicks K et al.: Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 104, 649-654 (2004). (Pubitemid 38970556)
191. Brown ER, Charles KA, Hoare SA et al.: A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer. Ann. Oncol. 19, 1340-1346 (2008).
192. Knutson KL, Disis ML: Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54, 721-728 (2005).
193. Becker Y: Molecular immunological approaches to biotherapy of human cancers - a review, hypothesis and implications. Anticancer Res. 26, 1113-1134 (2006).
194. + T cells in tumor immunotherapy due t o their efficient cytotoxicity, prolonged survival and type 1 immune modulation. Cell Mol. Immunol. 4, 277-285 (2007).
195. Sasaki K, Pardee AD, Okada H, Storkus WJ: IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. Eur. J. Immunol. 38, 2865-2873 (2008).
196. Dobrzanski MJ, Reome JB, Hylind JC, Rewers-Felkins KA, Abulsamad K, Adams SL: Ag-specific type 1 CD8 effector cells enhance methotrexate-mediated antitumor responses by modulating differentiated T cell localization, activation and chemokine production in established breast cancer. Clin. Immunol. 128, 205-218 (2008).
197. Nishimura T, Iwakabe K, Sekimoto M et al.: Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J. Exp. Med. 190, 617-627 (1999).
198. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 136, 2348-2357 (1986).
199. Ellison CA, Fischer JM, HayGlass KT, Gartner JG: Murine graft-versus-host disease in an F1-hybrid model using IFN-γ gene knockout donors. J. Immunol. 161, 631-640 (1998).
200. Brok HP, Heidt PJ, van der Meide PH, Zurcher C, Vossen JM: Interferon-γ prevents graft-versus-host disease after allogeneic bone marrow transplantation in mice. J. Immunol. 151, 6451-6459 (1993). (Pubitemid 2023407)
201. Wall DA, Sheehan KC: The role of tumor necrosis factor and interferon γ in graft-versus-host disease and related immunodeficiency. Transplantation 57, 273-279 (1994).
202. Sawitzki B, Kingsley CI, Oliveira V, Karim M, Herber M, Wood KJ: IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J. Exp. Med. 201, 1925-1935 (2005).
203. Carlson MJ, West ML, Coghill JM, Panoskaltsis-Mortari A, Blazar BR, Serody JS: In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood 113, 1365-1374 (2009).
204. Asavaroengchai W, Wang H, Wang S et al.: An essential role for IFN-γ in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant 13, 46-55 (2007). (Pubitemid 46044099)
205. Dey BR, Yang YG, Szot GL, Pearson DA, Sykes M: Interleukin-12 inhibits graft-versus-host disease through an Fas-mediated mechanism associated with alterations in donor T-cell activation and expansion. Blood 91, 3315-3322 (1998).
206. Sykes M, Szot GL, Nguyen PL, Pearson DA: Interleukin-12 inhibits murine graft-versus-host disease. Blood 86, 2429-2438 (1995).
207. Reddy P, Teshima T, Kukuruga M et al.: Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J. Exp. Med. 194, 1433-1440 (2001).
208. + regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood 108, 1571-1579 (2006). (Pubitemid 44316124)
209. Sun Y, Tawara I, Toubai T, Reddy P: Pathophysiology of acute graft-versus-host disease: recent advances. Transl. Res. 150, 197-214 (2007).
210. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132 (2005).
211. + T cells. J. Immunol. 155, 2396-2406 (1995).
212. + T cells. J. Immunol. 164, 664-669 (2000). (Pubitemid 30043686)
213. bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 97, 2948-2956 (2001).
214. +, Tc1/Tc2 populations in murine GVL: type I cells generate GVL and type II cells abrogate GVL. Biol. Blood Marrow Transplant 2, 118-125 (1996). (Pubitemid 126488208)
215. Hashimoto D, Asakura S, Miyake S et al.: Stimulation of host NKT cells by synthetic glycolipid regulates acute graft-versus-host disease by inducing Th2 polarization of donor T cells. J. Immunol. 174, 551-556 (2005). (Pubitemid 40007446)
216. Foley JE, Mariotti J, Ryan K, Eckhaus M, Fowler DH: Th2 cell therapy of established acute graft-versus-host disease requires IL-4 and IL-10 and is abrogated by IL-2 or host-type antigen-presenting cells. Biol. Blood Marrow Transplant 14, 959-972 (2008).
217. + T cells as augmentation of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant 12, 1150-1160 (2006).
218. Blazar BR, Murphy WJ: Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD). Philos. Trans. R. Soc. Lond. B Biol. Sci. 360, 1747-1767 (2005).
219. Matte CC, Cormier J, Anderson BE et al.: Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood 103, 4353-4361 (2004). (Pubitemid 38685384)
220. Ciceri F, Bonini C, Marktel S et al.: Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. Blood 109, 4698-4707 (2007). (Pubitemid 46827761)
221. Macatonia SE, Doherty TM, Knight SC, O'Garra A: Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-γ production. J. Immunol. 150, 3755-3765 (1993).
222. Mitra RS, Judge TA, Nestle FO, Turka LA, Nickoloff BJ: Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B7-1 (CD80) and B7-2 (CD86) expression. J. Immunol. 154, 2668-2677 (1995).
223. Rissoan MC, Soumelis V, Kadowaki N et al.: Reciprocal control of T helper cell and dendritic cell differentiation. Science 283, 1183-1186 (1999). (Pubitemid 129504124)
224. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J. Exp. Med. 174, 1209-1220 (1991).
225. Nishiki S, Hato F, Kamata N et al.: Selective activation of STAT3 in human monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-α production. Am. J. Physiol. Cell Physiol. 286, C1302-11 (2004).
226. Gruber MF, Williams CC, Gerrard TL: Macrophage-colony-stimulating factor expression by anti-CD45 stimulated human monocytes is transcriptionally up-regulated by IL-1 β and inhibited by IL-4 and IL-10. J. Immunol. 152, 1354-1361 (1994).
227. Chung EY, Liu J, Homma Y et al.: Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 27, 952-964 (2007). (Pubitemid 350251222)
228. Berkman N, John M, Roesems G, Jose PJ, Barnes PJ, Chung KF: Inhibition of macrophage inflammatory protein-1 α expression by IL-10. Differential sensitivities in human blood monocytes and alveolar macrophages. J. Immunol, 155, 4412-4418 (1995).
229. Rossi DL, Vicari AP, Franz-Bacon K, McClanahan TK, Zlotnik A: Identification through bioinformatics of two new macrophage proinflammatory human chemokines: MIP-3α and MIP-3β. J. Immunol. 158, 1033-1036 (1997). (Pubitemid 127469921)
230. Kopydlowski KM, Salkowski CA, Cody MJ et al.: Regulation of macrophage chemokine expression by lipopolysaccharide in vitro and in vivo. J. Immunol. 163, 1537-1544 (1999).
231. + T cell-mediated graft-versus-host disease. Transplantation 66, 1220-1229 (1998). (Pubitemid 28530328)
232. Liem LM, van Houwelingen HC, Goulmy E: Serum cytokine levels after HLA-identical bone marrow transplantation. Transplantation 66, 863-871 (1998).
233. Atkinson K, Matias C, Guiffre A et al.: In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation. Blood 77, 1376-1382 (1991).
234. Krenger W, Snyder K, Smith S, Ferrara JL: Effects of exogenous interleukin-10 in a murine model of graft-versus-host disease to minor histocompatibility antigens. Transplantation 58, 1251-1257 (1994).
235. Blazar BR, Taylor PA, Smith S, Vallera DA: Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts. Blood 85, 842-851 (1995).
236. Yonemura Y, Kawakita M, Miyake H, Miyazoe T, Fujimoto K, Takatsuki K: Effects of interleukin-11 on carboplatin-induced thrombocytopenia in rats and in combination with stem cell factor. Int. J. Hematol. 65, 397-404 (1997).
237. Ciurea SO, Hoffman R: Cytokines for the treatment of thrombocytopenia. Semin. Hematol. 44, 166-182 (2007).
238. Krijanovski OI, Hill GR, Cooke KR et al.: Keratinocyte growth factor separates graft-versus-leukemia effects from graft-versus-host disease. Blood 94, 825-831 (1999).
239. Teshima T, Hill GR, Pan L et al.: IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J. Clin. Invest. 104, 317-325 (1999).
240. Panoskaltsis-Mortari A, Lacey DL, Vallera DA, Blazar BR: Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92, 3960-3967 (1998). (Pubitemid 28525223)
241. Hill GR, Cooke KR, Teshima T et al.: Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest. 102, 115-123 (1998).
242. Antin JH, Lee SJ, Neuberg D et al.: A Phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant 29, 373-377 (2002). (Pubitemid 34262638)
243. Vanclee A, Lutgens LC, Oving EB et al.: Keratinocyte growth factor ameliorates acute graft-versus-host disease in a novel nonmyeloablative haploidentical transplantation model. Bone Marrow Transplant 36, 907-915 (2005). (Pubitemid 41655619)
244. Blazar BR, Weisdorf DJ, Defor T et al.: Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108, 3216-3222 (2006).
245. + CXC chemokine expression in synoviocytes and are overexpressed in rheumatoid blood. J. Immunol. 180, 655-663 (2008).
246. Liu SJ, Tsai JP, Shen CR et al.: Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6. J. Leukoc. Biol. 82, 354-360 (2007).
247. Roark CL, Simonian PL, Fontenot AP, Born WK, O'Brien RL: γδ T cells: an important source of IL-17. Curr. Opin. Immunol. 20, 353-357 (2008).
248. Bettelli E, Korn T, Kuchroo VK: Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 19, 652-657 (2007).
249. Korn T, Bettelli E, Gao W et al.: IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 448, 484-487 (2007). (Pubitemid 47123515)
250. Zheng Y, Danilenko DM, Valdez P et al.: Interleukin-22, a Th17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445, 648-651 (2007). (Pubitemid 46232884)
251. Kikly K, Liu L, Na S, Sedgwick JD: The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation. Curr. Opin. Immunol. 18, 670-675 (2006).
252. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006). (Pubitemid 43214587)
253. Kappel LW, Goldberg GL, King CG et al.: IL-17 contributes to CD4-mediated graft-versus-host disease. Blood113, 945-952 (2009).
254. Yi T, Zhao D, Lin CL et al.: Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood 112, 2101-2110 (2008).
255. Hattori K, Hirano T, Miyajima H et al.: Differential effects of anti-Fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies. Blood 91, 4051-4055 (1998). (Pubitemid 28261965)
256. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J: Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J. Exp. Med. 183, 657-661 (1996).
257. + donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis. Blood 98, 390-397 (2001).
258. + T cells during acute graft-versus-host disease. Blood 105, 2023-2027 (2005).
259. Hsieh MH, Varadi G, Flomenberg N, Korngold R: Leucyl-leucine methyl ester-treated haploidentical donor lymphocyte infusions can mediate graft-versus-leukemia activity with minimal graft-versus-host disease risk. Biol. Blood Marrow Transplant 8, 303-315 (2002). (Pubitemid 34784988)
260. Friedman TM, Filicko-O'Hara J, Mookerjee B et al.: T cell repertoire complexity is conserved after LLME treatment of donor lymphocyte infusions. Biol. Blood Marrow Transplant 13, 1439-1447 (2007). (Pubitemid 350091393)
261. de Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E: Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J. Immunol. 149, 1788-1794 (1992).
262. Hambach L, Vermeij M, Buser A, Aghai Z, van der Kwast T, Goulmy E: Targeting a single mismatched minor histocompatibility antigen with tumor-restricted expression eradicates human solid tumors. Blood 112, 1844-1852 (2008).
263. Savani BN, Mielke S, Adams S et al.: Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 21, 2145-2152 (2007). (Pubitemid 47423804)
264. Rezvani K, Barrett AJ: Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract. Res. Clin. Haematol. 21, 437-453 (2008).
265. Greiner J, Dohner H, Schmitt M: Cancer vaccines for patients with acute myeloid leukemia - definition of leukemia-associated antigens and current clinical protocols targeting these antigens. Haematologica 91, 1653-1661 (2006). (Pubitemid 46039635)
266. Oka Y, Tsuboi A, Taguchi T et al.: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA 101, 13885-13890 (2004).
267. Morita S, Oka Y, Tsuboi A et al.: A Phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the Phase I data. Jpn J. Clin. Oncol. 36, 231-236 (2006).
268. Rojas JM, Knight K, Wang L, Clark RE: Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 21, 2287-2295 (2007). (Pubitemid 350011701)
269. Soiffer R, Hodi FS, Haluska F et al.: Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J. Clin. Oncol. 21, 3343-3350 (2003).
270. Salgia R, Lynch T, Skarin A et al.: Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21, 624-630 (2003).
271. Vasir B, Wu Z, Crawford K et al.: Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J. Immunol. 181, 808-821 (2008).
272. Kaiser T, Kamal H, Rank A et al.: Proteomics applied to the clinical follow-up of patients after allogeneic hematopoietic stem cell transplantation. Blood 104, 340-349 (2004). (Pubitemid 38900013)
273. Weissinger EM, Schiffer E, Hertenstein B et al.: Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 109, 5511-5519 (2007). (Pubitemid 46890577)
274. Srinivasan R, Daniels J, Fusaro V et al.: Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp. Hematol. 34, 796-801 (2006).
275. Paczesny S, Krijanovski Ol, Braun TM et al.: A biomarker panel for acute graft-versus-host disease. Blood 113, 273-278 (2009).
276. Baron C, Somogyi R, Greller LD et al.: Prediction of graft-versus-host disease in humans by donor gene-expression profiling. PLoS Med. 4, E23 (2007). (Pubitemid 46191823)
277. Dickinson AM, Holler E: Polymorphisms of cytokine and innate immunity genes and GVHD. Best Pract. Res. Clin. Haematol. 21, 149-164 (2008).
278. Cullup H, Dickinson AM, Jackson GH, Taylor PR, Cavet J, Middleton PG: Donor interleukin 1 receptor antagonist genotype associated with acute graft-versus-host disease in human leucocyte antigen-matched sibling allogeneic transplants. Br. J. Haematol. 113, 807-813 (2001).
279. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A: Recipient interferon-γ 3/3 genotype contributes to the development of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Haematologica 90, 425-426 (2005). (Pubitemid 40389005)
280. Mlynarczewska A, Wysoczanska B, Karabon L, Bogunia-Kubik K, Lange A: Lack of IFN-γ 2/2 homozygous genotype independently of recipient age and intensity of conditioning regimen influences the risk of aGVHD manifestation after HLA-matched sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 34, 339-344 (2004). (Pubitemid 39172441)
281. Lin MT, Storer B, Martin PJ et al.: Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N. Engl. J. Med. 349, 2201-2210 (2003).
282. Middleton PG, Taylor PR, Jackson G, Proctor SJ, Dickinson AM: Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 92, 3943-3948 (1998). (Pubitemid 28525221)
283. Takahashi H, Furukawa T, Hashimoto S et al.: Contribution of TNF-α and IL-10 gene polymorphisms to graft-versus-host disease following allo-hematopoietic stem cell transplantation. Bone Marrow Transplant 26, 1317-1323 (2000). (Pubitemid 32098051)
284. Maruya E, Saji H, Seki S et al.: Evidence that CD31, CD49b, and CD62L are immunodominant minor histocompatibility antigens in HLA identical sibling bone marrow transplants. Blood 92, 2169-2176 (1998).
285. El-Chennawi FA, Kamel HA, Mosaad YM, El-Sherbini SM, El-Billey NA: Impact of CD31 mismatches on the outcome of hematopoeitic stem cell transplant of HLA-identical sibling. Hematology 11, 227-234 (2006).
286. Cavanagh G, Chapman CE, Carter V, Dickinson AM, Middleton PG: Donor CD31 genotype impacts on transplant complications after human leukocyte antigen-matched sibling allogeneic bone marrow transplantation. Transplantation 79, 602-605 (2005). (Pubitemid 40365890)